Loading...
•
Sep 30
Bristol-Myers Squibb Q3 2025 Earnings Report
Bristol Myers Squibb reported increased revenue and EPS in Q3 2025 driven by growth portfolio performance.
Key Takeaways
Bristol Myers Squibb delivered solid Q3 2025 results with strong growth in its new product portfolio and improved revenue, EPS, and net income. Legacy products declined but were offset by rising contributions from Breyanzi, Camzyos, and Reblozyl.
Revenue reached $12.2B, up from $11.9B in Q3 2024.
Non-GAAP EPS was $1.63, while GAAP EPS came in at $1.08.
Net income increased significantly year-over-year to approximately $2.2B.
Growth portfolio sales rose to $6.9B, surpassing legacy products.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
BMS raised full-year revenue guidance and maintained its EPS outlook, reflecting strong performance in the growth portfolio and strategic business execution.
Positive Outlook
- Raised FY2025 revenue guidance to $47.5–$48.0B.
- Growth portfolio continues to outperform expectations.
- Operating expense projections remain stable.
- Other income guidance increased to $500M due to royalties and licensing.
- Maintained gross margin outlook at ~72%.
Challenges Ahead
- Legacy portfolio sales expected to decline 15–17%.
- Revlimid sales forecasted at ~$3B due to continued erosion.
- IPR&D charges impacting EPS by $0.80 per share.
- No updates to OpEx improvement initiatives.
- Continued pressure from generic competition in EU and U.S.